soul study semaglutide Updates in Medicine | 🩺 Oral Cuts CV Risk in High-Risk T2DM – Trial (NEJM, Mar 2025) 🔗 Original article link in bio 📌 Key Highlights: 🔹 Semaglutide cardiovascular outcomes align more

Hidden Curriculum - teachers and clinicians directly point out "unspoken" social rules

Semaglutiidi kummikommid , kui uuenduslik ravimi annustamisvorm, kombineerib seda kummikommide vormiga, et parandada patsientide ravisoostumust

M., & Lee, J

Patients should be advised to: Start with the lowest dose and increase slowly Eat smaller, more frequent meals Avoid high-fat foods Stay well-hydrated Safety monitoring should include vigilance for: Pancreatitis symptoms (severe persistent abdominal pain) discontinue immediately if suspected Gallbladder disease increased risk with rapid weight loss Hypoglycaemia particularly when combined with insulin or sulphonylureas Renal function deterioration especially with dehydration from gastrointestinal effects Diabetic retinopathy monitor in patients with pre-existing retinopathy, particularly with semaglutide Suspected adverse reactions should be reported via the MHRA Yellow Card scheme

At 48 weeks, the 8 mg group showed 22.8% mean body weight reduction, exceeding maximum tirzepatide dosing results

Bower, J